Herishanu Y, et al. - In elderly patients with previously untreated chronic lymphocytic leukemia (CLL) enrolled in this single arm, phase 2 trial, researchers tested a regimen consisting of lower-dose fludarabine and cyclophosphamide combined with a standard dose of rituximab (LD-FCR). Effectiveness and safety analyses were performed with 40 patients who received LD-FCR and two patients treated with FC alone, respectively. The study population had median age 72.7 years and 67.5% and 42.5% were the overall response and complete response rates, respectively. The median progression-free survival (PFS) of 35.5 months was noted. The most common complications were hematological toxicities and infections. Overall, the efficacy, as well as relative safety of LD-FCR, was evident in previously untreated patients with CLL. It is important to consider recent findings highlighting longer PFS with good safety profile in fit elderly patients using the combination of bendamustine and rituximab.